GRAYCARY. TECHNOLOGY'S LEGAL EDGE®

4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133
www.graycary.com

O] 858-677-1400
F] 858-677-1465

FAX TRANSMISSION COVER SHEET

February 21, 2003

To:	Telephone:	Fax Number:
Examiner Spivack, Art Unit 1614 USPTO	**(703)308-4703**	**(703) 308-4556**

From: Lisa A. Haile, J.D., Ph.D.
858-677-1456

Client-Matter Number: 101668-17

FAX RECEIVED
FEB 23 2003
GROUP 1600

Re: **United States Patent Application No.: 09/889,251**
Entitled: METHODS OF TREATING MITOCHONDRIAL DISORDERS
Inventor: Robert K. Naviaux
Filed: November 1, 2001
Our Ref. No.: UCSD1140-1

OFFICIAL

Pages: - 2 - (including this form) Originals: ☒ will be mailed ☐ will not be mailed

If there is a problem with this transmission, please call (858) 638-6715/Carrie Bickle

Message:

In advance of our telephone interview scheduled for Monday, February 24, 2003, following for your review is an alternative version of claim 1 in the above-identified application. The alternative claim language set forth herein likely serves as a good starting point for our discussion on Monday.

Gray Cary\GT\6335837.1
101668-17

(Form Rev. 6/5/00)

Gray Cary\GT\6335837.1
101668-17

1. (Amended) A method for the treatment of a mitochondrial disorder comprising administering to a subject having or at risk of having such disorder an effective amount of a compound of Formula I:



(I)

wherein:

R_1 is O, OH, $NHCOCH_3$, or NH_2,

R_2 is H, CO_2H, or



wherein:

each X is independently H or optionally substituted C_1-C_{22} alkyl, optionally substituted C_1-C_{22} alkenyl, or optionally substituted C_1-C_{22} alkynyl, with substituents selected from the group consisting of H, C_1-C_3 alkyl, OH, NH_2, and halogen,

R_3, R_4, and R_5 are each independently optionally substituted C_1-C_{22} alkyl carbonyl, with substituents selected from the group consisting of C_1-C_3 alkyl, OH, NH_2, and halogen, or H, wherein at least one of R_3, R_4, and R_5, are not H, and

wherein the administration of a compound of Formula (I) augments *de novo* synthesis of pyrimidines in a cell intended to be so treated,

thereby treating the disorder.